Detergent Regulatory Watch | Why Microbial Cleaning Products Need to Keep Strain Identity, Safety Assessment, Spray Form, and Efficacy Claims Separate in Record-Keeping

Regulation (EU) 2026/405 was adopted on February 11, 2026, and published in the Official Journal of the European Union on March 2. Article 37 of the regulation stipulates that, except for individual provisions, it will mainly apply from September 23, 2029; Article 36 sets out separate transitional arrangements. Therefore, as of September 24, 2026, it should be written as implementation preparation and regulation monitoring, rather than mistakenly referring to all obligations as having come fully into effect.

This regulation establishes clearer product boundaries for detergents containing microorganisms for the first time. It requires that microorganisms can be clearly identified and supported by safety data and risk assessments for their use. For R&D and regulatory teams, this means that records cannot be limited to terms like 'probiotics,' 'biocleaning,' or a specific brand name; at a minimum, the specific microorganism identity, source, formulation version, intended use, dosage, and conditions of use must be traceable.

Microbial identity and finished product efficacy are two separate chains of evidence. Confirming which microorganism it is and whether it has known safety issues does not equate to proving that the finished product is effective on a certain stain, surface, or under specific usage conditions; conversely, observing cleaning effects cannot replace a safety assessment at the strain level. Project records should keep identity verification, safety data, finished product stability, and efficacy testing separately, and then combine them in the final declaration according to the applicable scope.

EFSA's QPS framework can help understand this tiered approach: microorganisms with unclear identity or safety concerns cannot rely on a simplified pre-assessment and require a more comprehensive safety review. However, QPS itself serves a specific regulatory assessment context; it is not a certification for finished detergents, nor can it be claimed that a household cleaning product is 'naturally safe' or has already obtained EU approval based on it.

Spray forms need to be accounted for separately. During the legislative negotiation phase, the Council of the European Union specifically discussed the respiratory exposure and sensitization risks posed by microbial detergents in spray form, and proposed directions for warnings, instructions, and restrictions. Negotiation materials are not a substitute for final regulatory obligations, but they remind that having the same formulation does not mean that liquid, spray, refill, and professional-use versions have the same exposure conditions.

Boundary statements also should not be mixed together. The final regulations clearly distinguish the ordinary cleaning positioning of microbial detergents from antibacterial and disinfectant effects; if the description falls under the regulation scope of biocidal products, it cannot be supported solely by the detergent formula or general cleaning tests. The name, icons, usage scenarios, before-and-after comparisons, and social media copy on the packaging can all collectively influence how consumers perceive the effectiveness.

Therefore, an executable R&D ledger should at least link six types of objects: microbial identity and supplier information, formulations and change records, dosage forms and packaging, target use scenarios, stability and safety assessments, and external declarations and corresponding tests. Any change must check whether it affects labels, digital data, test reports, or target market versions, rather than just modifying a single line in the formulation sheet.

EPHYON's publicly available cleaning-product ODM service page describes formulation adjustment, sample confirmation and packaging coordination. It also distinguishes domestic label guidance from the customer's responsibility to confirm compliance in the target export market. This supports a project workflow of requirements, samples, final artwork, production and document versions, but it does not prove that EPHYON has manufactured microbial detergents, owns particular strains or has completed an EU regulatory review.

The brand owner and the manufacturer should also agree on the burden of evidence at the start of the project. The brand owner needs to clarify the target market and planned claims; the formulation and raw materials team provides information on identity, composition, and changes; the manufacturer keeps sealed samples, batch records, and production consistency records; and the third-party laboratory is only responsible for the actual tested samples, methods, and conclusions. Clearly defining the roles can reduce the risk of having to retroactively gather evidence after marketing materials have been finalized.

Scope: This article is an industry observation based on the EU final regulation available as of September 24, 2026, legislative materials from the European Parliament and the Council, EFSA, the European Commission, and EPHYON public service information. It is not legal, microbial-safety or product-efficacy advice. Whether a particular product is a microbial detergent, whether a claim may be used, and which materials are required must be assessed case by case against the final formula, dosage form, intended use, target market and professional review.